PainReform down 38% after resuming trading

Shares of PainReform (PRFX) are down $1.84, or 38%, to $3.06 in pre-market trading after the company reported that following further investigation, PainReform has determined that the data from the final 24-hour period could not be clarified to satisfy the study’s primary endpoint 72 hours requirement, and therefore, the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy did not meet the primary endpoint of the study.